Axithra
9 known investors
Axithra develops a photonics-based device using Raman spectroscopy on a chip to measure the free, active fraction of drugs in patient blood for bedside therapeutic drug monitoring. The technology, aimed at healthcare professionals and targeting antibiotics, oncology drugs, and antifungals, is under development and clinical investigation and not yet commercially available.
Investors · 9
Kurma PartnersParis · $162K – $10.8M
Qbic FundSt-Denijs-Westrem
White FundLiège · $2.2M – $5.4M
imec.xpandreportedLeuven · $270K – $5.4M
Wallonie EntreprendrereportedLiège
Also in the syndicate · 4
Hamamatsu PhotonicsNoshaqQbicWerfen Diagnostics
Funding
SEC filings, press & company announcements- Undisclosed amountseed roundSep 2023
imec.xpand (lead), Kurma Partners (lead), Hamamatsu Photonics, Noshaq, Qbic, Wallonie Entreprendre, Werfen Diagnostics, White Fund
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Axithra do?
- Axithra develops a photonics-based device using Raman spectroscopy on a chip to measure the free, active fraction of drugs in patient blood for bedside therapeutic drug monitoring. The technology, aimed at healthcare professionals and targeting antibiotics, oncology drugs, and antifungals, is under development and clinical investigation and not yet commercially available.
- Who are Axithra's investors?
- Axithra's investors include Kurma Partners, Qbic Fund, White Fund, imec.xpand, Wallonie Entreprendre.